Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients.
about
Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecanComment on a published paper. The adverse cholinergic effects of the chemotherapeutic agent irinotecan (CPT-11) were unlikely to be mediated by the inhibition of acetylcholinesterase (AChE)Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer.The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours.Ugt1a is required for the protective effect of selenium against irinotecan-induced toxicity.Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy.A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer.Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status.Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy.Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates.Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.
P2860
Q28345820-356CC044-6E21-476F-BBB7-C819F77FCA2AQ28359545-1C562E4C-BF06-4D21-A2B9-48C117EB335EQ35826887-289657FC-0B68-41B4-AE8F-7C42318E3613Q35827631-5B0D67E4-C7B9-4649-8635-D966F53C95E0Q35857153-0DBD05B8-762A-4F69-BF92-94FCCA78ACC2Q36441493-B7B80F8F-AD2B-4850-8ECD-66638E231A6FQ36615856-17F70DD8-E623-49E9-977C-951CDF6EDEA5Q36641418-B1BDD63B-9918-40E6-B456-47F8D1DF5114Q37141536-C3ADB316-B49A-47F3-A27A-A5AB329C9BACQ37378223-A6974FCB-EF87-4291-B9AC-7891D43A99E1Q37402888-A1F4E46A-898B-4008-9782-51FD78D0C35CQ37731433-DB3844FA-32B1-4CAC-B4B9-5E209B0B1BAD
P2860
Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Identification and properties ...... d from the plasma of patients.
@ast
Identification and properties ...... d from the plasma of patients.
@en
type
label
Identification and properties ...... d from the plasma of patients.
@ast
Identification and properties ...... d from the plasma of patients.
@en
prefLabel
Identification and properties ...... d from the plasma of patients.
@ast
Identification and properties ...... d from the plasma of patients.
@en
P2093
P1433
P1476
Identification and properties ...... d from the plasma of patients.
@en
P2093
A Commerçon
L P Rivory
M Vuilhorgne
P304
P407
P577
1996-08-01T00:00:00Z